These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 10588170)

  • 21. Management of irritable bowel syndrome.
    Prior A; Whorwell PJ
    Biomed Pharmacother; 1986; 40(1):4-5. PubMed ID: 3011142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
    Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D;
    Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds.
    Callahan MJ
    J Clin Gastroenterol; 2002 Jul; 35(1 Suppl):S58-67. PubMed ID: 12184141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH; Luthin DR
    Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tegaserod and other serotonergic agents: what is the evidence?
    Chey WD
    Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New drugs in the management of the irritable bowel syndrome.
    Farthing MJ
    Drugs; 1998 Jul; 56(1):11-21. PubMed ID: 9664195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
    Lembo T; Wright RA; Bagby B; Decker C; Gordon S; Jhingran P; Carter E;
    Am J Gastroenterol; 2001 Sep; 96(9):2662-70. PubMed ID: 11569692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.
    Mangel AW; Northcutt AR
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():77-82. PubMed ID: 10429745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of irritable bowel syndrome.
    Trinkley KE; Nahata MC
    J Clin Pharm Ther; 2011 Jun; 36(3):275-82. PubMed ID: 21545610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Entry criteria for drug trials of irritable bowel syndrome.
    Kamm MA
    Am J Med; 1999 Nov; 107(5A):51S-58S. PubMed ID: 10588173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment goals in irritable bowel syndrome.
    Kellow JE
    Int J Clin Pract; 2001 Oct; 55(8):546-51. PubMed ID: 11695076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic strategy for the irritable bowel syndrome.
    Castiglione F; Daniele B; Mazzacca G
    Ital J Gastroenterol; 1991 Nov; 23(8 Suppl 1):53-5. PubMed ID: 1661628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
    Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
    Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of drug treatment in irritable bowel syndrome.
    Talley NJ
    Br J Clin Pharmacol; 2003 Oct; 56(4):362-9. PubMed ID: 12968980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathogenesis and management of irritable bowel syndrome.
    Mathew P; Bhatia SJ
    Trop Gastroenterol; 2009; 30(1):19-25. PubMed ID: 19624083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Common gastrointestinal symptoms: irritable bowel syndrome.
    Fashner J; Gitu AC
    FP Essent; 2013 Oct; 413():16-23. PubMed ID: 24124703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.
    Cremonini F; Delgado-Aros S; Camilleri M
    Neurogastroenterol Motil; 2003 Feb; 15(1):79-86. PubMed ID: 12588472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.